Overview of COVID-19’s relationship with thrombophilia proteins


Creative Commons License

Aydin S., UĞUR K., Yalcin H., Sahin I., AKKOÇ R. F. , YAKAR B., ...More

Turkish Journal of Biochemistry, vol.46, no.6, pp.609-622, 2021 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Review
  • Volume: 46 Issue: 6
  • Publication Date: 2021
  • Doi Number: 10.1515/tjb-2021-0183
  • Journal Name: Turkish Journal of Biochemistry
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, Food Science & Technology Abstracts, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.609-622
  • Keywords: anticoagulant, COVID-19, thrombophilia, thrombosis, FACTOR-V-LEIDEN, INHERITED ANTITHROMBIN DEFICIENCY, DEEP-VEIN THROMBOSIS, C RESISTANCE, S DEFICIENCY, VENOUS THROMBOEMBOLISM, PROTHROMBIN G20210A, COFACTOR-II, D-DIMER, METHYLENETETRAHYDROFOLATE REDUCTASE
  • Lokman Hekim University Affiliated: Yes

Abstract

© 2021 De Gruyter. All rights reserved.COVID-19 is the most devastating pandemic situation we have experienced in our age, affecting all systems. Although it affects all systems, it shows its most important effect through thrombophilia. Therefore, the possible cause of sudden death due to COVID-19 may be embolism caused by thrombophilia. D-dimer amounts increase due to COVID-19. The thrombosis is associated with sudden death in COVID-19 disease in populations. Since individuals with thrombophilia will be more prone to death due to COVID-19, it may be appropriate to administer low doses of Clexane (Enoxaparin sodium) or low-weight heparin for prophylactic purposes in order to consider these individuals at high risk and to prevent deaths. Moreover, in order not to risk the lives of healthcare professionals with thrombophilia, it would be appropriate to keep them away from individuals with COVID-19 disease and to employ them in different healthcare services according to their fields of expertise. It should also not be forgotten that different symptoms related to COVID-19 appear day by day, these different symptoms probably show that the virus has undergone mutations in order to survive, but no matter what, its effect on thrombophilia has not been eliminated yet. This compilation aims to present the reasons and causes of death due to COVID-19, possible treatment options, and thrombophilia panel tests and new parameters that may have a place in the meticulous interpretation of these tests and possible etiopathology in the light of current information. Therefore, presenting this information in a rational manner and keeping the parameters of the thrombophilia panel under strict control predict that the deaths due to the virus will be partially reduced.